Biodexa Pharmaceuticals Plc (BDRX) Comparison with companies in other sectors?

Biodexa Pharmaceuticals Plc has a share price of 32.00. You can analyze Biodexa Pharmaceuticals Plc (BDRX) competitors across different market sectors through stock heatmaps.

What are BDRX's NET and operating margins?

Biodexa Pharmaceuticals Plc (BDRX) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does BDRX's earnings per share (EPS) trend reflect its financial momentum?

Biodexa Pharmaceuticals Plc (BDRX) EPS is -133.59 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Biodexa Pharmaceuticals Plc is -0.05, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Biodexa Pharmaceuticals Plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Biodexa Pharmaceuticals Plc like P/E which is -0.06, P/B which is 0.04, and PEG which is 0.04. Compare them with sector averages to evaluate if the stock is priced fairly.

Biodexa Pharmaceuticals Plc

BDRX•NASDAQ

Healthcare

Biotechnology

$6.70

$-1.15(-14.65%)

Biodexa Pharmaceuticals Plc (BDRX) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-133.59

P/E Ratio

-0.05

ROE

-0.67%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$215.00

Shares OutstandingTotal number of shares issued

$32.00

Book Value/ShareNet worth per share

$134.33

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-133.59

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

-67.21%

ROAReturn on total assets

-38.76%

ROCEReturn on capital employed

-94.39%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-210.40

Cash/ShareCash and equivalents per share

$26.94

FCF YieldFree cash flow as percentage of market cap

-7970956.00%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BDRXFinancial Ratios Analysis details for BDRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BDRXSector Benchmarking details for BDRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Biodexa Pharmaceuticals Plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Biodexa Pharmaceuticals Plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Biodexa Pharmaceuticals Plc's unique business strengths and challenges.

Key Financial Metrics for Biodexa Pharmaceuticals Plc

For Biodexa Pharmaceuticals Plc, essential financial indicators include EPS -133.59, PE -0.05, and ROE -0.67. These key ratios reveal insights into Biodexa Pharmaceuticals Plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Biodexa Pharmaceuticals Plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Biodexa Pharmaceuticals Plc

Metrics like Net Margin - and ROA -38.76% shed light on how well Biodexa Pharmaceuticals Plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Biodexa Pharmaceuticals Plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Biodexa Pharmaceuticals Plc

Using ratios such as P/B Ratio 0.04 and PEG Ratio 0.04, investors can assess whether Biodexa Pharmaceuticals Plc is appropriately valued based on its financials and growth potential. These figures, combined with Biodexa Pharmaceuticals Plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Biodexa Pharmaceuticals Plc

Financial health indicators, such as Debt/Equity Ratio 0.09 and Cash Flow $-210.40, provide a snapshot of Biodexa Pharmaceuticals Plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Biodexa Pharmaceuticals Plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Biodexa Pharmaceuticals Plc

Investing in Biodexa Pharmaceuticals Plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Biodexa Pharmaceuticals Plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;